BRPI0816412A2 - forma de dosagem, e, método para tratar uma infecção bacteriana - Google Patents

forma de dosagem, e, método para tratar uma infecção bacteriana

Info

Publication number
BRPI0816412A2
BRPI0816412A2 BRPI0816412A BRPI0816412A BRPI0816412A2 BR PI0816412 A2 BRPI0816412 A2 BR PI0816412A2 BR PI0816412 A BRPI0816412 A BR PI0816412A BR PI0816412 A BRPI0816412 A BR PI0816412A BR PI0816412 A2 BRPI0816412 A2 BR PI0816412A2
Authority
BR
Brazil
Prior art keywords
treating
dosage form
bacterial infection
bacterial
infection
Prior art date
Application number
BRPI0816412A
Other languages
English (en)
Portuguese (pt)
Inventor
Dedhiya Mahendra
Ge Yigong
Original Assignee
Forest Laboratories Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40468354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0816412(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forest Laboratories Holdings Ltd filed Critical Forest Laboratories Holdings Ltd
Publication of BRPI0816412A2 publication Critical patent/BRPI0816412A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0816412A 2007-09-21 2008-09-19 forma de dosagem, e, método para tratar uma infecção bacteriana BRPI0816412A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97419407P 2007-09-21 2007-09-21
PCT/US2008/076920 WO2009039324A1 (en) 2007-09-21 2008-09-19 Soluble dosage forms containing cephem derivatives suitable for parenteral administration

Publications (1)

Publication Number Publication Date
BRPI0816412A2 true BRPI0816412A2 (pt) 2017-05-16

Family

ID=40468354

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816412A BRPI0816412A2 (pt) 2007-09-21 2008-09-19 forma de dosagem, e, método para tratar uma infecção bacteriana

Country Status (11)

Country Link
US (3) US20090082326A1 (enExample)
EP (2) EP2200618A4 (enExample)
JP (1) JP2010540448A (enExample)
KR (1) KR101599560B1 (enExample)
CN (3) CN103919720A (enExample)
AU (1) AU2008302201A1 (enExample)
BR (1) BRPI0816412A2 (enExample)
CA (1) CA2700263A1 (enExample)
MX (1) MX2010003112A (enExample)
RU (1) RU2537237C2 (enExample)
WO (1) WO2009039324A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012500528A1 (en) * 2009-09-21 2019-06-14 Astrazeneca Ab Compositions and methods for treating bacterial infections using caftaroline
AR088372A1 (es) * 2011-10-19 2014-05-28 Otsuka Pharma Co Ltd Solucion para administracion oral
WO2016008393A1 (zh) * 2014-07-14 2016-01-21 正大天晴药业集团股份有限公司 头孢罗膦氨基酸盐及其结晶
CN104258403B (zh) * 2014-09-28 2017-03-01 刘宗侠 一种西洛他唑组合物及其制备方法
KR20170038214A (ko) * 2015-09-30 2017-04-07 (주)아모레퍼시픽 당산 및 플라보노이드를 포함하는 항균용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028355A (en) * 1974-01-23 1977-06-07 Smithkline Corporation Cephalosporin purification process
GB8729574D0 (en) * 1987-12-18 1988-02-03 Fujisawa Pharmaceutical Co Water-soluble antibiotic composition
JPH02124822A (ja) * 1988-11-02 1990-05-14 Eisai Co Ltd セファロスポリン含有注射用組成物
JP2761005B2 (ja) * 1988-11-02 1998-06-04 エーザイ株式会社 セファロスポリン含有注射用組成物
EP0395219B1 (en) * 1989-03-30 1998-09-30 Pfizer Inc. Cephalosporins and their homologues, process for their preparation and pharmaceutical compositions
DE69004921T2 (de) * 1989-09-30 1994-05-05 Eisai Co Ltd Injizierbare Cephalosporinpräparate und ihre Anwendung.
JPH0840907A (ja) * 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd セファロスポリン注射剤
TW473479B (en) 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
EP2020416A1 (en) * 2000-08-10 2009-02-04 Takeda Pharmaceutical Company Limited Phosphonocephem compound
JP3586226B2 (ja) * 2000-08-10 2004-11-10 武田薬品工業株式会社 ホスホノセフェム化合物
WO2004096279A1 (ja) * 2003-04-28 2004-11-11 Takeda Pharmaceutical Company Limited 注射用組成物

Also Published As

Publication number Publication date
AU2008302201A1 (en) 2009-03-26
JP2010540448A (ja) 2010-12-24
CA2700263A1 (en) 2009-03-26
CN102935065A (zh) 2013-02-20
MX2010003112A (es) 2010-08-11
RU2010115268A (ru) 2011-10-27
WO2009039324A1 (en) 2009-03-26
KR101599560B1 (ko) 2016-03-03
EP2200618A4 (en) 2010-11-03
KR20100075942A (ko) 2010-07-05
US20090082326A1 (en) 2009-03-26
CN101868240A (zh) 2010-10-20
US20150196572A1 (en) 2015-07-16
EP2200618A1 (en) 2010-06-30
RU2537237C2 (ru) 2014-12-27
EP2952195A1 (en) 2015-12-09
US20120010180A1 (en) 2012-01-12
CN103919720A (zh) 2014-07-16

Similar Documents

Publication Publication Date Title
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0815387A2 (pt) composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
PL2190883T3 (pl) Sposób obróbki biomasy
ZA200906349B (en) Combination medicaments for treating bacterial infections
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
BRPI0721502A2 (pt) Método para tratamento de uma formação fraturada
BRPI0912111A2 (pt) composto, composição farmacêutica, método para tratar, controlar ou prevenir uma doença ou distúrbio, e, forma de dosagem unitária única
BRPI0820474A2 (pt) método de tratamento de uma doença, uso de composto, e, composto
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0811241A2 (pt) Instalação de tratamento a vácuo e método de tratamento a vácuo
BRPI0912337A2 (pt) composto método para melhorar memória em paciente, e, método para tratar condições
BRPI0814300A2 (pt) Composto, composição farmacêutica, e, método para tratar uma infecção viral
BRPI0810525A2 (pt) Composições e métodos para a profilaxia e tratamento de dependência química
BRPI0915382A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BR112013014133A2 (pt) lenço, método para remoção de bactérias a partir de uma superfície e concentrado antimicrobiano
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0821129A2 (pt) Métodos para a inibição de cicatrização
BRPI0915267A2 (pt) Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição
SE0702104L (sv) Förfarande för behandling av avfall
BR112013010738A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção viral
BRPI0718661A2 (pt) Método para prevenir o crescimento de microorganismos, e uma combinação para a prevenção do crescimento microbiano
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0810946A2 (pt) Método para tratamento de hérnia de disco
BRPI0916885A2 (pt) composição farmacêutica, e, método para tratar uma infecção bacteriana
BR112012016364A2 (pt) "método para fabricar produtos embutidos, embutidos e dispositivo de produção de embutidos"

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: PFIZER ANTI-INFECTIVES AB (SE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2740 DE 11-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.